New drug combination for advanced colorectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called HDM2017, which may help fight advanced colorectal cancer by targeting the CDH17 protein, combined with the usual treatments. It's for people whose cancer has spread and who haven't had certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have colorectal cancer that has spread or cannot be removed by surgery.
- You must be able to provide a sample of your tumor (either from an earlier biopsy or a new one).
- You must be in generally good health, able to take care of yourself and be up and about more than half of the day.
- You must not have had treatment with certain targeted therapies (called TKIs) or antibody-drug conjugates (ADCs) before.
- You must have at least one measurable tumor (visible on scans).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study tests a new drug called HDM2017 in combination with other treatments for advanced colorectal cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.